Figure 5
Figure 5. CINC-1 levels increase in the BALF from rats transfused with MHC class I abs. CINC-1 levels (ng/mL) were measured in the BAL fluid (BALF) via commercial ELISA and are shown as a function of treatment group: control rats injected with NS (■) or LPS () and infused with murine IgG isotype controls (0.30 mg/kg), OX18 (0.15-0.45 mg/kg), or OX27 (0.075-4.5 mg/kg). Rats injected with NS did not evidence increases in CINC-1 in the BALF nor did animals injected with LPS and then infused with NS, 0.15 mg/kg OX18 or 0.075 mg/kg OX18. However, in those groups in which ALI was seen, specifically rats injected with LPS and transfused with 0.30 to 0.45 mg/kg OX18 and 0.15 to 0.30 mg/kg OX27 had a significant increase in CINC-1 levels from LPS/NS and LPS/mouse IgG. (*P < .05 from LPS/NS; †P < .05 from LPS/mouse IgG, n = 4 for each group.)

CINC-1 levels increase in the BALF from rats transfused with MHC class I abs. CINC-1 levels (ng/mL) were measured in the BAL fluid (BALF) via commercial ELISA and are shown as a function of treatment group: control rats injected with NS (■) or LPS () and infused with murine IgG isotype controls (0.30 mg/kg), OX18 (0.15-0.45 mg/kg), or OX27 (0.075-4.5 mg/kg). Rats injected with NS did not evidence increases in CINC-1 in the BALF nor did animals injected with LPS and then infused with NS, 0.15 mg/kg OX18 or 0.075 mg/kg OX18. However, in those groups in which ALI was seen, specifically rats injected with LPS and transfused with 0.30 to 0.45 mg/kg OX18 and 0.15 to 0.30 mg/kg OX27 had a significant increase in CINC-1 levels from LPS/NS and LPS/mouse IgG. (*P < .05 from LPS/NS; †P < .05 from LPS/mouse IgG, n = 4 for each group.)

Close Modal

or Create an Account

Close Modal
Close Modal